ES2097207T3 - Receptor de poli-ig de sintesis, complejos receptor-anticuerpo, produccion y aplicacion de los mismos. - Google Patents

Receptor de poli-ig de sintesis, complejos receptor-anticuerpo, produccion y aplicacion de los mismos.

Info

Publication number
ES2097207T3
ES2097207T3 ES91909070T ES91909070T ES2097207T3 ES 2097207 T3 ES2097207 T3 ES 2097207T3 ES 91909070 T ES91909070 T ES 91909070T ES 91909070 T ES91909070 T ES 91909070T ES 2097207 T3 ES2097207 T3 ES 2097207T3
Authority
ES
Spain
Prior art keywords
receptor
domain
poli
complex
receiver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91909070T
Other languages
English (en)
Inventor
Jean-Pierre Kraehenbuhl
Richard A Weltzin
Marian R Neutra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Suisse de Recherches Experimentales sur le Cancer
Harvard University
Original Assignee
Institut Suisse de Recherches Experimentales sur le Cancer
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Suisse de Recherches Experimentales sur le Cancer, Harvard University filed Critical Institut Suisse de Recherches Experimentales sur le Cancer
Application granted granted Critical
Publication of ES2097207T3 publication Critical patent/ES2097207T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICUERPOS DE POLI-IG (EN PARTICULAR IGA MONOCLONALES) SE COMPLEJAN CON UNA PROTEINA ESTABILIZADORA DERIVADA DEL RECEPTOR DE POLI-IG (EN PARTICULAR DE UNA PROTEINA ESTABILIZADORA DERIVADA DE UN RECEPTOR RECOMBINANTE), QUE INCLUYE AL MENOS UN DOMINIO ENLAZADOR DE POLI-IG DEL RECEPTOR Y NO TIENE SUSTANCIALMENTE NINGUN DOMINIO DE LA TRANSMEMBRANA DE TERMINAL C NI DE NINGUNO DEL RECEPTOR DE POLI-IG INTRACELULAR. EL COMPLEJO ESTABILIZADO SE PUEDE UTILIZAR A MODO DE VACUNA PASIVA QUE SE ADMINISTRA A SUPERFICIES MUCOSAS. SIEMPRE SE PRESENTAN LOS METODOS PARA LA SEPARACION IN VIVO DEL POLI-IG MONOCLONAL. TAMBIEN SE PRESENTAN LOS METODOS PARA GENERAR EL COMPLEJO UTILIZANDO UNA MONOCAPA DE CELULAS EPITELIALES DEPENDIENTES DEL ANCLAJE REALIZADAS PARA HACER UN RECEPTOR DE POLI-IG. LAS HIBRIDOMAS PARA LA PRODUCCION DE IGA MONOCLONALES SE HACEN RECOGIENDO CELULAS LINFOIDEAS DEL TEJIDO MUCOSO (EJ. PEDAZOS DE PEYER) QUE CONTIENEN MUCHAS DE ESTAS CELULAS.
ES91909070T 1990-04-16 1991-04-16 Receptor de poli-ig de sintesis, complejos receptor-anticuerpo, produccion y aplicacion de los mismos. Expired - Lifetime ES2097207T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51016190A 1990-04-16 1990-04-16

Publications (1)

Publication Number Publication Date
ES2097207T3 true ES2097207T3 (es) 1997-04-01

Family

ID=24029610

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91909070T Expired - Lifetime ES2097207T3 (es) 1990-04-16 1991-04-16 Receptor de poli-ig de sintesis, complejos receptor-anticuerpo, produccion y aplicacion de los mismos.

Country Status (21)

Country Link
EP (1) EP0480014B1 (es)
JP (1) JPH05501118A (es)
KR (1) KR920702625A (es)
CN (1) CN1057785A (es)
AT (1) ATE145137T1 (es)
AU (2) AU7792691A (es)
BG (1) BG95634A (es)
BR (1) BR9105717A (es)
CA (1) CA2059289A1 (es)
DE (1) DE69123121T2 (es)
DK (1) DK0480014T3 (es)
ES (1) ES2097207T3 (es)
FI (1) FI915881A0 (es)
GR (1) GR3022512T3 (es)
HU (1) HUT63059A (es)
NO (1) NO914946L (es)
OA (1) OA09647A (es)
RO (1) RO109703B1 (es)
RU (1) RU2124050C1 (es)
WO (1) WO1991016061A1 (es)
ZA (1) ZA912837B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
EP0675734A4 (en) * 1992-12-21 1997-05-07 Tanox Biosystems Inc ALLERGY SPECIFIC, MONOCLONAL IgA ANTIBODIES AND SIMILAR PRODUCTS FOR ALLERGY TREATMENT.
US6046037A (en) * 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US6808709B1 (en) 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
WO1996021012A1 (en) 1994-12-30 1996-07-11 Planet Biotechnology, Inc. Methods for producing immunoglobulins containing protection proteins in plants and their use
EP0839915A1 (en) * 1996-11-01 1998-05-06 Institut Suisse De Recherches Experimentales Sur Le Cancer Isrec Secretory immunoglobulin A as a mucosal vaccine delivery system
ATE442386T1 (de) 2000-04-28 2009-09-15 Planet Biotechnology Inc Immunoadhesin zur impfung gegen rhinovirus
AU2001272908A1 (en) 2000-05-10 2001-11-20 David A. Sirbasku Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers
RU2186390C1 (ru) * 2001-01-26 2002-07-27 Научно-исследовательский институт эпидемиологии и микробиологии им. Н.Ф. Гамалеи РАМН Способ выделения пневмоцист
GB201101429D0 (en) * 2011-01-27 2011-03-16 Biocompatibles Uk Ltd Drug delivery system
CN104903727B (zh) * 2012-11-08 2019-10-22 马克法兰伯尼特医学研究与公共健康协会有限公司 诊断、预后、治疗和筛选方案
RU2605321C1 (ru) * 2015-07-16 2016-12-20 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Фракция днк-гидролизующих секреторных иммуноглобулинов класса а, обладающая избирательной апоптотической активностью по отношению к раковым клеткам человека

Also Published As

Publication number Publication date
JPH05501118A (ja) 1993-03-04
AU687443B2 (en) 1998-02-26
DE69123121T2 (de) 1997-04-03
BG95634A (bg) 1993-12-24
DE69123121D1 (de) 1996-12-19
AU7792691A (en) 1991-11-11
EP0480014A1 (en) 1992-04-15
HUT63059A (en) 1993-07-28
BR9105717A (pt) 1992-07-21
NO914946L (no) 1992-02-12
DK0480014T3 (da) 1997-02-17
GR3022512T3 (en) 1997-05-31
NO914946D0 (no) 1991-12-13
ZA912837B (en) 1992-03-25
OA09647A (en) 1993-04-30
FI915881A7 (fi) 1991-12-13
AU7771594A (en) 1995-04-06
CA2059289A1 (en) 1991-10-17
WO1991016061A1 (en) 1991-10-31
FI915881A0 (fi) 1991-12-13
RO109703B1 (ro) 1995-05-30
EP0480014A4 (en) 1992-10-14
CN1057785A (zh) 1992-01-15
KR920702625A (ko) 1992-10-06
HU9200136D0 (en) 1992-04-28
RU2124050C1 (ru) 1998-12-27
EP0480014B1 (en) 1996-11-13
ATE145137T1 (de) 1996-11-15

Similar Documents

Publication Publication Date Title
ES2076142T3 (es) Peptidos para el diagnostico de anticuerpos para htlv-iii, su preparacion y uso.
CO4480110A1 (es) Neutralizacion de anticuerpos monoclonales humanos de alta afinidad especificos para proteina - f rsv y metodos para su fabricacion y uso terapeutico de los mismos
MXPA03002412A (es) Compuestos de succinimida heterociclicos fusionados y analogos de los mismos, moduladores de la funcion del receptor de la hormona nuclear.
WO2004001007A3 (en) Buffered formulations for concentrating antibodies and methods of use thereof
EA200100509A1 (ru) Модифицированные экзосомы и их применение
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
DE69333397D1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
MX9203605A (es) Proteina receptora de ctla4 codificada por secuencia de amino acido.
ATE144143T1 (de) Künstlicher impfstoff gegen aids-virus
ES2194836T3 (es) Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
DE69132671D1 (de) Protein-g-gekoppelte glutaminsäure-rezeptoren
ES8500997A1 (es) Un metodo para producir un peptido.
ES2078971T3 (es) Produccion de virus y purificacion de proteinas con envoltura virica para uso en vacunas.
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
MX9702666A (es) Nuevos peptidos con efectos inmunoreguladores.
ES2070820T3 (es) Anticuerpos monoclonales especificos de la apolipoproteina b, producidos por dos nuevos hibridomas.
DE59610251D1 (de) Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
ATE237343T1 (de) Retropeptide, antikörper dagegen und deren verwendungen in der impfung und in vitro diagnostik
BR9105717A (pt) Receptor poli-ig sintetico,complexos de receptor-anticorpo,sua producao e uso
ES2118720T3 (es) Produccion y utilizacion de agentes antihelminticos e inmunogenos protectores.
SE8100614L (sv) Humant relaxin och sett for framstellning derav
BR9611947A (pt) Isoindolonas fundidas como inibidores da quinase da proteina c
ES2061566T3 (es) Anticuerpos monoclonales contra la proteina e7 del papilomavirus humano tipo 16, procedimiento para su preparacion, asi como su empleo.
MX9102647A (es) Nueva proteina capaz de inducir una respuesta inmunoprotectora contra la infeccion causada por toxoplasma gondii y para clonar y expresar un gen que codifica a la proteina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 480014

Country of ref document: ES